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http://dx.doi.org/10.1016/j.stemcr.2017.07.016SUMMARYMesoderm derived from human embryonic stem cells (hESCs) is a major source of the mesenchymal stem/stromal cells (MSCs) that can
differentiate into osteoblasts and chondrocytes for tissue regeneration. While significant progress has been made in understanding of
molecular mechanisms of hESC differentiation into mesodermal cells, little is known about epigenetic factors controlling hESC fate
towardmesoderm andMSCs. Identifying potential epigenetic factors that control hESC differentiationwill undoubtedly lead to advance-
ments in regenerative medicine. Here, we conducted an epigenome-wide analysis of hESCs andMSCs and uncovered that EZH2 was en-
riched in hESCs and was downregulated significantly inMSCs. The specific EZH2 inhibitor GSK126 directed hESC differentiation toward
mesoderm and generatedmoreMSCs by reducingH3K27me3. Our results provide insights into epigenetic landscapes of hESCs andMSCs
and suggest that inhibiting EZH2 promotes mesodermal differentiation of hESCs.INTRODUCTION
Mesenchymal stem/stromal cells (MSCs) are attractive
sources for a large number of cell-based therapies due to
their self-renewal capacity and multi-lineage differentia-
tion potential into bone, cartilage, and adipose tissues
(Bianco et al., 2013; Alvarez et al., 2015). Amajor limitation
of MSC-based therapy is that isolation of MSCs from bone
marrow is an invasive process with potential adverse effects
for the donor. Additionally, the proliferation and differen-
tiation capacity ofMSCs can vary between different donors
with notable decreases as the donor patient age increases
(Kern et al., 2006). Thus, while MSCs isolated from bone
marrow exhibit a promising potential for bone regenera-
tion, there are shortcomings that may limit their overall
effectiveness.
MSCs derived fromhuman embryonic stem cells (hESCs)
represent an attractive alternative particularly for bone
regeneration because they have higher proliferation and
osteogenic potential (Barlow et al., 2008; Giuliani et al.,
2011). Several groups have developed a variety of methods
to derive MSCs from ESCs that are biologically and pheno-
typically similar to bone marrowMSCs (Brown et al., 2009;
Deng et al., 2016). However, although there has been sig-
nificant progress in developing protocols for hESC differen-
tiation into MSCs, the differentiating or epigenetic pro-
gramming of hESCs is a rather slow process that does not
fulfill the requirements of tissue regeneration. Mesoderm752 Stem Cell Reports j Vol. 9 j 752–761 j September 12, 2017 j ª 2017 The
This is an open access article under the CC BY-NC-ND license (http://creativderived from hESCs is a major source of multiple potent
MSCs. Therefore, it is critical to identify potential inducing
signals or epigenetic factors that might help to promote
mesodermal differentiation of hESCs.
The highly conserved polycomb group (PcG) proteins are
epigenetic modulators that carry out histone methylation
to initiate andmaintain the transcriptional repressive state
of genes associated with differentiation to retain stem cell
pluripotency in hESCs (Boyer et al., 2006; Deng et al.,
2015). Mammalian PcG proteins are classified as two
distinct complexes, the polycomb repressive complexes
1 and 2 (PRC1 and PRC2).While PRC1 recognizes the chro-
modomain of H3K27me3 to facilitate ubiquitination of
H2AK119, PRC2 mediates the trimethylation of H3K27 at
gene promoters. As a critical subunit of PRC2, EZH2 cata-
lyzes the addition of methyl groups to H3K27 through
the SET domain of its carboxy-terminal region and serves
as a recruitment platform for DNA methyltransferases for
gene silencing (Cao et al., 2002). Here, we performed epige-
nome-wide comparisons of the transcriptome and histone
modifications between hESCs and human ESC-derived
MSCs using publicly available RNA sequencing (RNA-seq)
and chromatin immunoprecipitation sequencing (ChIP-
seq) data. This epigenome-wide map revealed that EZH2
was enriched in hESCs and was downregulated signifi-
cantly in MSCs. We found that reducing H3K27me3 epige-
netically promoted mesodermal differentiation of hESCs
and generated more MSCs with multipotency.Author(s).
ecommons.org/licenses/by-nc-nd/4.0/).
RESULTS
EZH2 Expression Is Decreased Following hESC
Differentiation into MSCs
To generate the specific gene expression profile of MSCs
following hESC differentiation, we used the RNA-seq data
available from the NIH Roadmap Epigenomics project
(Xie et al., 2013). The gene expression profiles of hESCs
and three hESC-derived lineages showed gene clusters
that were either upregulated or downregulated in MSCs
compared with hESCs (Figure 1A). Gene ontology (GO)
analysis indicated that upregulated genes are highly en-
riched in categories related to skeletal systemdevelopment,
embryonic morphogenesis, and cell migration (Figure 1B),
whereas downregulated genes are enriched in categories
related to mitosis, organelle fission, DNA replication and
repair, and chromosome function (Figure 1C). As the
importance of epigenetic regulation in ESC differentiation
is well established, we next examined the expression of
epigenetic modulators (Figure 1D). Among these, EZH2,
JARID2, and DNMT3B were the three most downregulated
genes in MSCs compared with hESCs. Specifically, these
epigenetic modulators are involved in repressive function,
with EZH2 and JARID2 being associated with the trimethy-
lation of H3K27 and DNMT3B with the methylation of
DNA (Chedin, 2011) (Figure 1D). qRT-PCR confirmed
that JARID2, EZH2, SUV39H1, and KDM6Awere downregu-
lated in hESC-derived MSCs (Figures S1A and S1B). Since
EZH2 and JARID2 are both components of PRC2, we inves-
tigated the gene expression of each individual PRC2
component. Comparative analysis of hESCs and MSCs
revealed that all members of PRC2, EZH2, SUZ12, EED,
RbAp48, and JARID2 are reduced in MSCs compared with
hESCs (Figure 1E). While JARID2 exhibited the most signif-
icant decrease, its downregulation was observed in all
three hESC-derived lineages (Figure 1E). Surprisingly, the
downregulation of EZH2 was specific to MSCs, with its
upregulation observed in the other hESC-derived lineages
(Figure 1E). Consistently, protein expression of EZH2
decreased dramatically after 3 days of hESC differentiation
(Figure 1F).Decreasing H3K27me3 on Specific Gene Clusters
Associated with hESC Programming into MSCs
Both silencing H3K27me3 and activating H3K4me3 epige-
netic marks, referred to as bivalent domains, occupy the
EZH2-targeted genes in ESCs, working together to preserve
ESC pluripotency and mediate rapid responses to differen-
tiation signals (Bernstein et al., 2006). Therefore, to further
examine the epigenetic basis of hESC differentiation into
MSCs, we profiled H3K27me3 and H3K4me3 marks in
hESCs and MSCs with the use of ChIP-seq data (Xie et al.,2013). Consequently, we identified 8,314 and 4,732 biva-
lent genes—those with binding sites for both H3K4me3
and H3K27me3—in H1 hESCs andMSCs, respectively (Fig-
ure 2A). Our data further indicated that, while there are
3,650 common bivalent genes in both H1 hESCs and
MSCs, 4,664 bivalent genes disappear and 1,082 genes
emerge solely in MSCs (Figure 2B, upper). We then selected
developmental regulator genes that are bivalent in hESCs,
but only have binding sites for H3K4me3—and are there-
fore transcriptionally active—in MSCs, identifying 3,982
genes (Figure 2B, lower). These genes are enriched for pro-
tein kinase activity, blood vessel development, and,
notably, skeletal development (Figure 2C). Among them,
we identified BMP4, HOXC5, and TWIST1 (Figure 2D),
genes that have been known to play a role in MSC
behavior, thereby demonstrating that histone profiles can
independently predict key hESC to MSC differentiation
regulators.
We grouped the histone profiles of 3,087 RefSeq genes,
whose expression levels were upregulated in MSCs. Clus-
tering of the signal around the transcription start site
(TSS) shows that H3K4me3 and H3K27me3 can be classi-
fied into two distinct clusters (Figure 2E). Cluster 1 heat-
map showed high intensity and wide coverage (mean
3,200 bp) of H3K4me3 and H3K27me3 in H1 ESCs.
Notably, H3K4me3 was also enriched around the TSS of
MSCs, where H3K27me3 enrichment was absent. Cluster
2 showed no significant enrichment of either epigenetic
signature within 5 kb of the TSS for both H1 ESCs and
MSCs (Figure 2E). Interestingly, GO analysis using the func-
tional annotation tool, DAVID Bioinformatics Resources
6.7, revealed that the co-presence of H3K4me3 and
H3K27me3 at the TSS in hESCs, with little or no co-occu-
pancy in MSCs, caused strong functional enrichment for
genes involved in skeletal system development, embryonic
development, and blood vessel development (Figure 2F).
Genes enriched in cluster 2 were involved in signal trans-
duction and cell proliferation (p < 108) (Figure 2G). We
also examined the H3K4me3 and H3K27me3 enrichment
peaks around the TSS of genes that were downregulated
in MSCs and found that they can be classified into three
distinct clusters (Figure S1C). Cluster 1 contained a wide
distribution of H3K4me3 in H1 ESCs that co-occupied
with H3K27me3. Cluster 2 showed enrichment of
H3K4me3 in both H1 ESCs and MSCs, while cluster 3
showed no significant enrichment of either histone mark
in both H1 ESCs andMSCs (Figure S1C). Importantly, clus-
ter 1 displayed a combination of decreased H3K4me3
enrichment, and increased H3K27me3 enrichment was
observed in downregulated genes. Among these genes,
GO analysis indicated that those that were the most down-
regulated in MSCs compared with hESCs are involved in
cell signaling, synaptic transmission, cell-cycle processes,Stem Cell Reports j Vol. 9 j 752–761 j September 12, 2017 753
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Figure 1. Transcriptome Alterations in H1 hESC-Derived Lineages
(A) Heatmaps showing the expression levels of coding genes in H1 hESCs and H1 hESC-derived cell lineages.
(B and C) Gene ontology (GO) enrichment analysis for upregulated genes (B) and downregulated genes (C) in H1 hESC-derived MSCs. The GO
terms include biological function. Bars represent log10 of p values.
(D) Fold changes of FPKM (fragments per kilobase of transcript per million mapped reads) value for genes encoding epigenetic modifiers in
H1 hESC-derived lineages comparing with H1 hESCs. The y axis shows the log scale. Data are shown as mean ± SD from 2 replicates of RNA-
seq data.
(E) Average FPKM value of genes encoding core components of PRC2 complex in H1 hESCs and H1 hESC-derived lineages. Data are shown as
mean ± SD from 2 replicates of RNA-seq data. *p < 0.05; **p < 0.01.
(F) Western blot analysis of EZH2 level during differentiation of H1 hESCs to MSC.
See also Figure S1.
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Figure 2. Histone Marks in H1 hESC-Derived MSCs
(A) The classification of RefSeq genes in terms of enrichment of H3K4me3 and H3K27me3 in H1 hESCs and H1 hESC-derived MSCs. Both and
H3K4me3 co-occupy with H3K27me3.
(B) Venn diagram showing bivalent domains change during hESC differentiation toward MSCs.
(C) GO enrichment analysis of genes that were developmental regulators (bivalent in ESCs) and were activated in MSCs (lose H3K27me3).
Bars represent log10 of p values.
(D) Representative peak tracks of H3K4me3 and H3K27me3 enrichment along BMP4, HOXC5, and TWIST1 genes in H1 hESCs and H1 hESC-
derived MSCs.
(E) Profiles of H3K4me3 and H3K27me3 around TSS of genes that upregulated in MSCs. Red represents high intensity and white represents
no signal. The profile plot shows the average reads at each relative position to TSS on the x axis with H3K4me3 and H3K27me3 coverage.
(F) GO enrichment analysis of cluster 1 genes. Bars represent log10 of p values.
(G) GO enrichment analysis of cluster 2 genes. Bars represent log10 of p values.
See also Figure S1.
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chromosomal organization, and organelle fission (Figures
S1D–S1F).
Inhibition of EZH2 Directs hESC Differentiation
toward Mesoderm and Generates More MSCs
Next, we sought to understand the role of EZH2 in the
differentiation of hESCs into MSCs. We treated hESCs
with GSK126, a highly selective and potent inhibitor of
EZH2. Western blot analysis showed that GSK126 potently
inhibited EZH2’s histone methyltransferase activity in
hESCs, as demonstrated by an evident reduction in
H3K27me3 (Figure 3A). Alkaline phosphatase (ALP) stain-
ing showed that GSK126 treatment dramatically inhibited
ALP activities in both H1 and H9 hESCs (Figure S2). We as-
sessed the effects of EZH2 inactivation on the expression
pattern of markers for the three germ layers. qRT-PCR re-
vealed that multiple mesodermal markers, including KDR,
FOXF1, MSX1, T, and GATA4, were significantly elevated
upon GSK126 treatment (Figures 3B–3D). On the contrary,
GSK126 significantly inhibited the expression of the ecto-
dermal mark gene TUBB3 and the endodermal gene
SOX17 and had a minimal effect on the expression of the
ectodermal marker gene PAX6 and endodermal marker
gene FOXA2. Flow cytometry via fluorescence-activated
cell sorting (FACS) staining confirmed that GSK126 treat-
ment promoted KDR expression while it did not affect
the expression of PAX6 and FOXA2 (Figure S2B). Interest-
ingly, a similar pattern was seen in H9 hESCs, but with
even more pronounced changes (Figures 3E–3G and S2C).
GO enrichment analysis of EZH2 ChIP-seq data in H1
hESCs revealed that EZH2 is enriched at the promoters of
genes involved in developmental processes such as skeletal
development and pattern specification (Figure 3H). To rule
out the non-specific effect of GSK126, we knocked down
EZH2 in hESCs using small interfering RNA (siRNA) (Fig-
ure 3I). Consistently, siRNA-mediated EZH2 depletion
also led to enhanced expression of mesodermal markers
(Figure 3J).
Since the mesoderm is a major source of the mesen-
chymal precursors that enable the formation of skeletal
and connective tissues (Vodyanik et al., 2010), we further
explored lineage specification to MSCs by examining
MSC surface markers. qRT-PCR analysis indicated that the
mRNA levels of CD73, CD146, and CD271 were signifi-
cantly upregulated following 3 days of GSK126 treatment
in H1 hESCs (Figure 4A) and H9 ESCs (Figure S3A) in a
dose-dependent manner. Such enhanced expression of
MSC markers was further confirmed by flow-cytometry
analysis (Figures 4B and S2C).
Since the inhibition of EZH2 by GSK126 appeared to
generate more mesenchymal precursors from hESCs, we
examined whether these differentiated cells from hESCs
could be induced to differentiate into osteoblasts, chondro-756 Stem Cell Reports j Vol. 9 j 752–761 j September 12, 2017cytes, or adipocytes. We first treated H1 hESCs with either
GSK126 or a vehicle control for 3 days, then transitioned
them to amonolayer and cultured them in appropriate dif-
ferentiation media. When these cells were induced to un-
dergo osteogenic differentiation with osteogenic induction
(OI) medium for 14 days, both ALP activity and the capac-
ity to formmineralized nodules were significantly elevated
in hESCs treated with GSK126 compared with the vehicle
control (Figures 4C and 4D). Consistently, real-time RT-
PCR showed elevated expression levels of osteogenic
markers including ALPL, RUNX2, IBSP, and BGLAP (Fig-
ure 4F). Furthermore, we evaluated the chondrogenic
capacity of differentiated hESCs with or without GSK126
treatment. Following treatment with chondrogenic induc-
tion (CI) medium for 21 days, GSK126-treated hESCs
showed enhanced chondrogenic potential demonstrated
by the presence of increased glycosaminoglycans and
increased expression of chondrogenic markers SOX9 and
COL2A1 (Figure 4E). Comparable results were also observed
in GSK126-treated H9 hESCs compared with vehicle treat-
ment (Figures S3C–S3G). Interestingly, we were unable to
induce adipogenic differentiation in these unsorted cells
(data not shown).
Next, we sought to determine whether the increased
osteogenic potentials following GSK126 treatment was
due to an enhanced potency of individual mesenchymal
precursors or a generation of more MSCs from hESCs. In
general, MSCs positively express multiple cell-surface
markers, including CD51, CD73, CD90, CD146, and
CD271, and are negative for CD34 and CD45. To accom-
plish this, we treated H1 hESCs with either GSK126 or a
vehicle control for 3 days. Subsequently, cells were trypsi-
nized to generate a single-cell suspension for further
differentiation for 5 days and then sorted by flow cytome-
try. Our preliminary analysis found that more than 95% of
the cells were positive for CD51 and CD90 (Figures S4A
and S4C) and negative for CD34 (Figures S4B and S4D).
Therefore, we utilized the combination of markers
CD73+CD146+CD271+CD45– to isolate MSCs from differ-
entiating hESCs excluding CD51, CD90, and CD34. FACS
analysis indicated that, whereas 2.8% MSCs (H1-MSC-V)
from differentiating hESCs without GSK126 treatment
were isolated, GSK126 treatment generated an approxi-
mately 3-fold greater number of MSCs (H1-MSC-126) (Fig-
ure 4H). Since GSK126 treatment yielded more MSCs, it
was important to demonstrate whether accelerating MSC
fates by an epigenetic modifier did not impair the multiple
potentials of MSCs from the aspect of regenerative medi-
cine. The isolated H1-MSC-126 and H1-MSC-V cells by
FACS were compared for their terminal differentiation
capacity to develop into osteoblasts, chondrocytes, and
adipocytes in the absence of GSK126. Importantly, ALP or
Alizarin red staining revealed that H1-MSC-126 had same
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(legend continued on next page)
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strong osteogenic potentials as H1-MSC-V (Figures 4I and
4J). Real-time RT-PCR showed that the expression of the
osteogenic markers in H1-MSC-126, including ALPL,
RUNX2, IBSP, and BGLAP, was induced at levels similar to
those in H1-MSC-V upon OI treatment (Figure 4K).
Following CI, both H1-MSC-126 and H1-MSC-V equiva-
lently differentiated into chondrocytes (Figure 4L). Un-
likely unsorted cells, both H1-MSC-126 and H1-MSC-V
could differentiate into adipocytes as determined by oil
red O staining. Real-time RT-PCR also confirmed that the
adipogenic markers PPARG and LPLwere similarly induced
in both H1-MSC-126 and H1-MSC-V (Figure 4M). To
further confirm our results, we also isolated MSCs from
H9 hESCs treated with or without GSK126 using
CD73+CD146+CD271+CD45 markers. Consistently, we
found that the inhibition of EZH2 by GSK126 also signifi-
cantly increased the proportion of MSCs from H9 hESCs
by 3-fold (Figure S3H). MSCs derived from GSK126-treated
H9 hESCs maintained osteogenic, chondrogenic, and adi-
pogenic potentials in vitro (Figures S3I–S3M).DISCUSSION
In this study, we identified an epigenetic mechanism that
facilitates controlled differentiation of pluripotent hESCs
into mesodermal lineage. Through a comparative analysis
of the transcriptome and epigenetic signatures between
hESCs and MSCs, we found that PRC2 components were
significantly downregulated in MSCs compared with
hESCs. Further analysis revealed that among the most
downregulated of PRC2 components in MSCs was EZH2.
EZH2 serves as an essential force in the epigenetic land-
scape of embryonic development by mediating the
silencing of a diverse group of developmental genes.
Indeed, obliterating EZH2’s function in replenishing
H3K27me3 repressive signatures disturbed the equilibrium
in the epigenetic landscape, leading to differentiation. Sur-
prisingly, however, we observed a discerning rise in the
expression of mesoderm and MSC markers and a concur-
rent decline in endoderm and ectoderm markers, indi-
cating EZH2’s distinguishing role in restricting commit-
ment to mesodermal lineage. Importantly, we showed
that the inhibition of EZH2 by the small-molecule inhibi-
tor GSK126 potently produced higher volumes of meso-
dermal progenitors fromhESCs, positioning EZH2 as a vital(E–G) qRT-PCR analysis of mesodermal genes (FOXF1, MSX1, T, KDR,
genes (SOX17, FOXA2) (G) for H9 cells treated with DMSO or GSK126.
(H) GO enrichment analysis of EZH2 enrichment within 1 kb of TSS fo
(I) Western blot analysis of EZH2 protein level after EZH2 siRNA knoc
(J) qRT-PCR analysis of mesodermal genes (FOXF1, MSX1, T, KDR, GAT
Data are shown as mean ± SD; n = 3 independent experiments. *p <
Figure S2.
758 Stem Cell Reports j Vol. 9 j 752–761 j September 12, 2017epigenetic modifier that regulates hESC differentiation
into mesodermal lineage.
Because MSCs demonstrate high osteogenic potential
with greater consistency and higher proliferation rate
compared with MSCs from bone marrow, they may be bet-
ter suited for regenerativemedicine. Here, we identified the
central epigenetic mechanism that directs hESCs to meso-
dermal linage as the incapacitation of EZH2 remodeled
the epigenetic landscape in favor of MSC derivation. These
results underscore a new duty of EZH2 in governing meso-
dermal commitment, beyond its established roles in ESC
identity preservation and terminal differentiation. Mecha-
nistically, when an inhibitor such as GSK126 binds to
EZH2, its histone methyltransferase activity on H3K27 is
disabled and repressive H3K27me3marks are no longer suf-
ficiently replenished, leading to disinhibition of target
genes. As increasing the efficiency of MSC production is
an important clinical goal, modulation of EZH2 will have
profound implications for the future of regenerative
medicine. While drugs targeting epigenetic modifiers are
currently being investigated for therapeutic use in the treat-
ment of cancer, autoimmune diseases, and neurological
disorders, we provide strong evidence that epigenetic mod-
ifiers can also be utilized for enriched acquisition of MSCs
with osteogenic potential from hESCs.EXPERIMENTAL PROCEDURES
Cell Culture and MSC Differentiation
The protocol for the hESCs study was approved by UCLA Embry-
onic stem cells research oversight committee (IRB: 10-001711-
CR-00001). H1 and H9 hESCs were obtained from the UCLA Broad
Stem Cell Research Center. hESCs were cultured on a mitotically
inactivated mouse embryonic feeder (MEF) layer, as previously
described (Thomson et al., 1998), and cells were maintained for
35–45 passages. hESC colonies were detached by type IV collage-
nase (1 mg/mL), plated onto Matrigel-coated tissue culture dishes,
and grown in mTeSR1 medium (catalog #85850, STEMCELL Tech-
nologies; Yu et al., 2011; Xie et al., 2013). Subsequently, GSK126
(10 mM; CAS #1346574-57-9, Cayman Chemical) was added to
the medium for 3 days every day. After 3 days of treatment, the
derived cells were trypsinized to generate a single-cell suspension
for further differentiation for 5 days and then sorted by flow cy-
tometry. Osteogenic, chondrogenic, and adipogenic differentia-
tion was induced as described previously (Chang et al., 2009;
Deng et al., 2016).GATA4) (E), ectodermal genes (TUBB3, PAX6) (F), and endodermal
r RefSeq genes in H1 hESCs.
kdown in H1 hESCs.
A4) after EZH2 siRNA knockdown.
0.05, **p < 0.01, and ***p < 0.001 by Student’s t test. See also
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Figure 4. Effect of GSK126 Treatment on Mesenchymal Lineage Commitment of H1 hESCs
(A) qRT-PCR gene expression analysis of well-known MSC surface markers (CD73, CD146, and CD271).
(B) Flow-cytometry analysis for CD73, CD146, and CD271 expression of cells treated with DMSO or GSK126.
(legend continued on next page)
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qRT-PCR
Total RNA was isolated using the RNeasy Micro kit (Qiagen). First-
strand cDNAwas synthesized using random hexamers and reverse
transcriptase according to the manufacturer’s protocol (Invitro-
gen). RT-PCR was performed using the QuantiTect SYBR Green
PCR kit (Qiagen) and the Icycler iQ Multi-color Real-time PCR
Detection System (Bio-Rad). The primers for GAPDH are 50-GGA
GCG AGA TCC CTC CAA AAT-30 (forward), 50-GGC TGT TGT
CAT ACT TCT CAT GG-30 (reverse). The primers for PAX6 are
50-TGG GCA GGT ATT ACG AGA CTG-30 (forward), 50-ACT CCC
GCT TAT ACT GGG CTA-30 (reverse). The primers for PDGFR-a
are 50-TAT GTG CCA GAC CCA GAT GT-30 (forward), 50-GGA
GTC TCG GGA TCA GTT GT-30 (reverse). The primers for CD73
are 50-TTA CAC AGG CAA TCC ACC TTC-30 (forward), 50-TTA
CAC AGG CAA TCC ACC TTC-30 (reverse). The primers for
CD146 are 50-CTG CTG AGT GAA CCA CAG GA-30 (forward),
50-CAC CTG GCC TGT CTC TTC TC-30 (reverse).
Flow Cytometry and Fluorescence-Activated Cell
Sorting
Cells were collected and washed twice with FACS buffer (PBS,
10 mM EDTA, and 2% fetal bovine serum) and suspended at a
maximum concentration of 2 3 105 cells per 100 mL. Cells were
incubated with antibodies for 30 min on ice in the dark, washed,
and suspended in PBS. Samples were analyzed on a BD LSR II
analyzer or sorted on a BD FACSAria III. Cell gating was based on
comparison with isotype-negative controls and single-stained
controls. Cells were sorted into serum-free DMEM for gene expres-
sion analysis or into complete medium for cell culture. Antibodies
used (all from BioLegend) included PE-CD34 (catalog #343606),
PerCP-Cy5.5-CD45 (#368506), PE-CD51 (#327910), APC-CD73
(#344006), FITC-CD90 (#328108), FITC-CD146 (#361012), and
PE-CD271 (#345106).
External Data Source, ChIP-Seq Data Analysis, and
RNA-Seq Data Analysis
Raw data for histone H3K4me3 and H3K27me3 ChIP-seq and
raw data for RNA-seq of hESCs and hESC-derived lineages were(C) ALP staining and quantitative ALP activity assay after 14 days of
bar, 300 mm.
(D) ARS staining and quantification after 14 days of OI for DMSO- or
(E) Alcian blue staining and quantification after 21 days of chond
bar, 440 mm.
(F and G) qRT-PCR gene expression analysis of osteogenic markers (A
and COL2a1) (G) after lineage-specific differentiation in H1 cells trea
(H) Proportions of CD90+CD146+CD271+CD45– H1-MSC-V and H1-MSC-
(I) ALP staining and quantitative ALP activity assay of H1-MSC-V and
(J) ARS staining and quantification of H1-MSC-V and H1-MSC-126 aft
(K) qRT-PCR gene expression analysis of osteogenic markers (ALPL, RUNX
(L) Alcian blue staining and quantification (left) and qRT-PCR gene exp
of H1-MSC-V and H1-MSC-126 after 21 days of CI. Scale bar, 440 mm.
(M) Oil red O staining and quantification (left) and qRT-PCR gene expre
MSC-V and H1-MSC-126 after 21 days of adipogenic induction (AI). S
Data are shown as mean ± SD; n = 3 independent experiments. *p < 0.0
S3 and S4.
760 Stem Cell Reports j Vol. 9 j 752–761 j September 12, 2017downloaded from the NCBI epigenome roadmap (http://www.
ncbi.nlm.nih.gov/geo/roadmap/epigenomics/). Data analysis was
performed as described in Supplemental Experimental Procedures.
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line at http://dx.doi.org/10.1016/j.stemcr.2017.07.016.
AUTHOR CONTRIBUTIONS
Y.Y., C.H., and C.Y.W. conceived of this study. Y.Y. and P.D. per-
formed most experiments and analyzed data. B.Y., J.M.S., C.H.,
and T.A. assisted P.D. for cell differentiation studies and flow cy-
tometry. Y.Y. performed bioinformatics. B.Y. and C.H. helped to
analyze the data. Y.Y., C.H., and C.Y.W. wrote the paper.
ACKNOWLEDGMENTS
This work was supported by the Shapiro Family Charitable Funds.
Flow cytometry was performed in the UCLA Flow Cytometry Core
Facility that is supported by NIH awards P30CA016042 and
5P30AI028697.
Received: August 24, 2016
Revised: July 19, 2017
Accepted: July 20, 2017
Published: August 17, 2017REFERENCES
Alvarez, R., Lee, H.L., Wang, C.Y., and Hong, C. (2015). Character-
ization of the osteogenic potential ofmesenchymal stem cells from
human periodontal ligament based on cell surface markers. Int. J.
Oral Sci. 7, 213–219.
Barlow, S., Brooke, G., Chatterjee, K., Price, G., Pelekanos, R., Ros-
setti, T., Doody, M., Venter, D., Pain, S., Gilshenan, K., et al. (2008).
Comparison of human placenta- and bone marrow-derived multi-
potent mesenchymal stem cells. Stem Cells Dev. 17, 1095–1107.osteogenic induction (OI) for DMSO- or GSK126-treated cells. Scale
GSK126-treated cells. Scale bar, 440 mm.
rogenic induction (CI) for DMSO- or GSK126-treated cells. Scale
LPL, RUNX2, IBSP, and BGLAP) (F) and chondrogenic markers (SOX9
ted with or without GSK126.
126 are compared.
H1-MSC-126 after 14 days of OI. Scale bar, 440 mm.
er 14 days of OI. Scale bar, 440 mm.
2, IBSP, and BGLAP) in H1-MSC-V and H1-MSC-126 after 14 days of OI.
ression analysis of chondrogenic markers (SOX9 and COL2a1) (right)
ssion analysis of adipogenic markers (PPARG and LPL) (right) of H1-
cale bar, 440 mm.
5, **p < 0.01, and ***p < 0.001 by Student’s t test. See also Figures
Bernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J.,
Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006).
A bivalent chromatin structure marks key developmental genes
in embryonic stem cells. Cell 125, 315–326.
Bianco, P., Cao, X., Frenette, P.S., Mao, J.J., Robey, P.G., Simmons,
P.J., andWang, C.Y. (2013). Themeaning, the sense and the signif-
icance: translating the science of mesenchymal stem cells into
medicine. Nat. Med. 19, 35–42.
Boyer, L.A., Plath, K., Zeitlinger, J., Brambrink, T., Medeiros, L.A.,
Lee, T.I., Levine, S.S., Wernig, M., Tajonar, A., Ray, M.K., et al.
(2006). Polycomb complexes repress developmental regulators in
murine embryonic stem cells. Nature 441, 349–353.
Brown, S.E., Tong, W., and Krebsbach, P.H. (2009). The derivation
of mesenchymal stem cells from human embryonic stem cells.
Cells Tissues Organs 189, 256–260.
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H.,
Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone H3
lysine 27 methylation in polycomb-group silencing. Science 298,
1039–1043.
Chang, J., Wang, Z., Tang, E., Fan, Z., McCauley, L., Franceschi, R.,
Guan, K., Krebsbach, P.H., and Wang, C.Y. (2009). Inhibition of
osteoblastic bone formation by nuclear factor-kappaB. Nat. Med.
15, 682–689.
Chedin, F. (2011). TheDNMT3 family ofmammaliandenovoDNA
methyltransferases. Prog. Mol. Biol. Transl. Sci. 101, 255–285.
Deng, P., Chen, Q.M., Hong, C., and Wang, C.Y. (2015). Histone
methyltransferases anddemethylases: regulators in balancingoste-
ogenic and adipogenic differentiation of mesenchymal stem cells.
Int. J. Oral Sci. 7, 197–204.Deng, P., Zhou,C., Alvarez, R., Hong, C., andWang, C.Y. (2016). In-
hibition of IKK/NF-kB signaling enhances differentiation of
mesenchymal stromal cells from human embryonic stem cells.
Stem Cell Reports 6, 456–465.
Giuliani, M., Fleury, M., Vernochet, A., Ketroussi, F., Clay, D., Az-
zarone, B., Lataillade, J.J., and Durrbach, A. (2011). Long-lasting
inhibitory effects of fetal liver mesenchymal stem cells on
T-lymphocyte proliferation. PLoS One 6, e19988.
Kern, S., Eichler, H., Stoeve, J., Klu¨ter, H., and Bieback, K. (2006).
Comparative analysis of mesenchymal stem cells from bone
marrow, umbilical cord blood, or adipose tissue. Stem Cells 24,
1294–1301.
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A.,
Swiergiel, J.J., Marshall, V.S., and Jones, J.M. (1998). Embryonic
stem cell lines derived from human blastocysts. Science 282,
1145–1147.
Vodyanik, M.A., Yu, J., Zhang, X., Tian, S., Stewart, R., Thomson,
J.A., and Slukvin, I.I. (2010). A mesoderm-derived precursor for
mesenchymal stem and endothelial cells. Cell Stem Cell 7,
718–729.
Xie, W., Schultz, M.D., Lister, R., Hou, Z., Rajagopal, N., Ray, P.,
Whitaker, J.W., Tian, S., Hawkins, R.D., Leung, D., et al. (2013). Ep-
igenomic analysis of multilineage differentiation of human em-
bryonic stem cells. Cell 153, 1134–1148.
Yu, P., Pan, G., Yu, J., and Thomson, J.A. (2011). FGF2 sus-
tains NANOG and switches the outcome of BMP4-induced
human embryonic stem cell differentiation. Cell Stem Cell
8, 326–334.Stem Cell Reports j Vol. 9 j 752–761 j September 12, 2017 761
